Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer

被引：0
|
作者：
Barnato, Sara E.
Jeruss, Jacqueline Sara
Bethke, Kevin P.
Hansen, Nora M.
Khan, Seema Ahsan
Von Roenn, Jamie H.
Rosen, Steven T.
Gradishar, William John
Siziopikou, Kalliopi P.
Meservey, Caitlin
Kaklamani, Virginia G.
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
[2] Lynn Sage Comprehens Breast Ctr, Chicago, IL USA
[3] Lynn Sage Comprehens Canc Ctr, Chicago, IL USA
[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1134
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial
    Di Cosimo, S.
    Laverde, N.
    Cazzaniga, M. E.
    Generali, D.
    Bianchi, G. V.
    Tagliabue, E.
    Torri, V.
    Crippa, F.
    Paolini, B.
    Scaperrotta, G.
    Gulino, A.
    Tripodo, C.
    Colombo, M. P.
    Folli, S.
    de Braud, F. G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] Phase II trial of neoadjuvant chemotherapy with carboplatin and nab-paclitaxel in patients with triple negative locally advanced and inflammatory breast cancer
    Somlo, G.
    Chung, S.
    Frankel, P.
    Hurria, A.
    Koehler, S.
    Kruper, L.
    Mortimer, J. E.
    Paz, B.
    Robinson, K.
    Taylor, L.
    Vito, C.
    Waisman, J.
    Yeon, C.
    Yim, J.
    Yuan, Y.
    Tong, T.
    CANCER RESEARCH, 2016, 76
  • [43] Phase I trial of eribulin and everolimus in patients with metastatic triple negative breast cancer
    Yuan, Y.
    Yost, S.
    Blanchard, S.
    Yin, H.
    Li, M.
    Robinson, K.
    Tang, A.
    Martinez, N.
    Leong, L.
    Somlo, G.
    Patel, N. Tank
    Waisman, J.
    Portnow, J.
    Hurria, A.
    Luu, T-H
    Mortimer, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer.
    Sikov, W. M.
    Perou, C. M.
    Golshan, M.
    Collyar, D.
    Berry, D. A.
    Hahn, O. M.
    Singh, B.
    Hudis, C.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)
    Von Minckwitz, Gunter
    Schneeweiss, Andreas
    Salat, Christoph
    Rezai, Mahdi
    Zahm, Dirk Michael
    Klare, Peter
    Blohmer, Jens U.
    Tesch, Hans
    Khandan, Fariba
    Jud, Sebastian
    Jackisch, Christian
    Mehta, Keyur
    Loibl, Sibylle
    Untch, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
    Kim, H. R.
    Jung, K. H.
    Im, S. -A.
    Im, Y. -H.
    Kang, S. Y.
    Park, K. H.
    Lee, S.
    Kim, S. -B.
    Lee, K. -H.
    Ahn, J. S.
    Kim, S. I.
    Sohn, J. H.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1485 - 1490
  • [47] Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer
    von Minckwitz, G.
    Timms, K.
    Untch, M.
    Elkin, E. P.
    Hahnen, E.
    Fasching, P. A.
    Schneeweiss, A.
    Salat, C. T.
    Rezai, M.
    Blohmer, J-U
    Zahm, D-M
    Jackisch, C.
    Gerber, B.
    Klare, P.
    Kummel, S.
    Paepke, S.
    Schmutzler, R.
    Chau, S.
    Reid, J.
    Hartman, A-R
    Nekljudova, V.
    Weber, K. E.
    Loibl, S.
    CANCER RESEARCH, 2017, 77
  • [48] Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
    Tolaney, Sara M.
    Kalinsky, Kevin
    Kaklamani, Virginia G.
    D'Adamo, David R.
    Aktan, Gursel
    Tsai, Michaela L.
    O'Regan, Ruth M.
    Kaufman, Peter A.
    Wilks, Sharon T.
    Andreopoulou, Eleni
    Patt, Debra A.
    Yuan, Yuan
    Wang, Grace
    Savulsky, Claudio
    Xing, Dongyuan
    Kleynerman, Ella
    Karantza, Vassiliki
    Diab, Sami
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3061 - 3068
  • [49] Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
    Shimomura, Akihiko
    Yonemori, Kan
    Yoshida, Masayuki
    Yoshida, Teruhiko
    Yasojima, Hiroyuki
    Masuda, Norikazu
    Aogi, Kenjiro
    Takahashi, Masato
    Naito, Yoichi
    Shimizu, Satoru
    Nakamura, Rikiya
    Hamada, Akinobu
    Michimae, Hirofumi
    Hashimoto, Jun
    Yamamoto, Harukaze
    Kawachi, Asuka
    Shimizu, Chikako
    Fujiwara, Yasuhiro
    Tamura, Kenji
    TRANSLATIONAL ONCOLOGY, 2019, 12 (10): : 1386 - 1394
  • [50] A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).
    Lander, Eric Michael
    Lehmann, Brian David
    Shah, Payal D.
    Dees, Elizabeth Claire
    Ballinger, Tarah Jean
    Pohlmann, Paula Raffin
    Santa-Maria, Cesar Augusto
    Shyr, Yu
    Mayer, Ingrid A.
    Park, Ben Ho
    Pietenpol, Jennifer A.
    Abramson, Vandana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345